HC Wainwright Cuts Earnings Estimates for Prime Medicine

Prime Medicine, Inc. (NYSE:PRME) – Equities research analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for Prime Medicine in a note issued to investors on Monday, August 11th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.31). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.45) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($1.00) EPS.

Several other research firms have also recently weighed in on PRME. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Prime Medicine in a report on Tuesday, May 20th. Chardan Capital dropped their price target on Prime Medicine from $12.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 8th. JMP Securities dropped their price target on Prime Medicine from $10.00 to $6.00 and set a “market outperform” rating for the company in a report on Tuesday, May 20th. Citigroup reissued a “neutral” rating and set a $1.50 price target (down from $10.00) on shares of Prime Medicine in a report on Tuesday, May 27th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Prime Medicine in a report on Wednesday, July 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.92.

Prime Medicine Stock Down 1.9%

PRME opened at $3.57 on Thursday. Prime Medicine has a 12-month low of $1.11 and a 12-month high of $5.17. The stock has a market cap of $480.43 million, a price-to-earnings ratio of -1.74 and a beta of 2.39. The business has a 50 day moving average of $3.32 and a 200-day moving average of $2.36.

Insider Buying and Selling at Prime Medicine

In other Prime Medicine news, major shareholder Arch Venture Partners Xii, Llc purchased 3,030,300 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were bought at an average price of $3.30 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider owned 6,230,300 shares in the company, valued at approximately $20,559,990. This trade represents a 94.70% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder David R. Liu purchased 21,000 shares of the firm’s stock in a transaction dated Monday, June 23rd. The stock was acquired at an average price of $2.16 per share, for a total transaction of $45,360.00. Following the purchase, the insider owned 20,219,945 shares in the company, valued at approximately $43,675,081.20. The trade was a 0.10% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 3,093,300 shares of company stock worth $10,110,240. Corporate insiders own 22.74% of the company’s stock.

Hedge Funds Weigh In On Prime Medicine

Several hedge funds and other institutional investors have recently modified their holdings of PRME. Creative Planning acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $25,000. Freedom Investment Management Inc. acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $26,000. R Squared Ltd acquired a new position in Prime Medicine during the 2nd quarter worth about $31,000. JTC Employer Solutions Trustee Ltd acquired a new position in Prime Medicine during the 2nd quarter worth about $33,000. Finally, Savant Capital LLC acquired a new position in Prime Medicine during the 2nd quarter worth about $37,000. Institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.